Syngen Biotech Co., Ltd. (8279)
TWSE
80.30
-1.20 (-1.47%)
Closed
Nov 6, 2026
Day's Range
78.6080.90
52 wk Range
77.60141.00
Financial Statements - 8279 - Syngen Biotech Co., Ltd.
Revenue
2.13B▲ 6.1%
Net Income
271.59M▲ 13.1%Net Margin 12.7%
EBITDA
458.80M▲ 6.6%
Free Cash Flow
243.06M▼ 14.3%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.13B | 2.01B | 1.83B | 1.93B | 1.47B | 1.31B |
| Cost of Goods | 1.41B | 1.28B | 1.19B | 1.24B | 942.92M | 816.02M |
| Gross Profit | 723.58M | 723.93M | 643.91M | 688.15M | 528.34M | 495.41M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 323.95M | 310.21M | 294.28M | 380.19M | 281.80M | 257.49M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 334.84M | 299.61M | 333.80M | 396.41M | 295.49M | 263.37M |
| Income Tax | 63.25M | 59.40M | 58.97M | 75.17M | 57.72M | 47.82M |
| Net Income | 271.59M | 240.20M | 274.82M | 321.23M | 237.77M | 215.55M |
| EPS Basic | 10.02 | 8.86 | 10.14 | 11.85 | 8.77 | 7.95 |
| EPS Diluted | 10.01 | 8.85 | 10.13 | 11.84 | 8.76 | 7.94 |
| Basic Shares Outstanding | 27.10M | 27.10M | 27.10M | 27.10M | 27.10M | 27.10M |
| Diluted Shares Outstanding | 27.10M | 27.10M | 27.10M | 27.10M | 27.10M | 27.10M |
| Ebit | 340.49M | 308.88M | 342.66M | 401.48M | 298.70M | 265.84M |
| Ebitda | 458.80M | 430.49M | 433.55M | 505.80M | 380.42M | 340.73M |
| Net Income Continuous Operations | 334.84M | 299.61M | 333.80M | 396.41M | 295.49M | 263.37M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
